RVMD Revolution Medicines, Inc.

159.43USD-0.24%Mkt Cap: 34.48B USDP/E: —

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that bind…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap34.48B USD
Enterprise Value32.13B USD
Revenue (TTM)197.56M USD
Gross Profit-1.30B USD
Net Income (TTM)-1.13B USD
Revenue/Share0.96 USD
Last Price159.43 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees883
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-50.58
PEG—
EV/EBITDA-19.18
EV/Revenue162.62
P/S174.55
P/B14.36
EPS (TTM)-8.92 USD
EPS (Forward)-3.10 USD
52W Range
58.9162% of range220.81
52W High220.81 USD
52W Low58.91 USD
Profitability
Gross Margin0.00%
Oper. Margin-852.98%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.35%
ROA-48.05%
ROIC—
ROCE-57.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-897.74M USD
CapEx (TTM)15.99M USD
FCF Margin-448.62%
FCF Yield-2.57%
Net Debt-2.44B USD
Net Debt/EBITDA1.46
Net Debt/FCF—
Balance Sheet
Debt/Equity0.10
Current Ratio8.36
Quick Ratio8.16
Book Value/Sh11.11 USD
Cash/Share16.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)274.68 USD
Upside (mean)+72.3%
Target Range179.00 USD – 350.00 USD
179.00+72.3% to mean350.00
# Analysts24
Ownership
Shares Out.216.29M
Float186.57M
Insiders1.83%
Institutions98.11%
Short Interest
Short Ratio6.8d
Short % Float6.38%
Short % Out.6.05%
Shares Short13.08M
Short (prev mo.)11.93M
Technical
SMA 50193.60 (-17.7%)
SMA 200160.23 (-0.5%)
Beta1.43
S&P 52W Chg12.08%
Avg Vol (30d)2.38M
Avg Vol (10d)3.26M
Technical Indicators
RSI (14)34.1
MACD-7.9814
MACD Signal-4.9091
MACD Hist.-3.0723
BB Upper207.88 USD
BB Middle182.54 USD
BB Lower157.20 USD
BB Width27.76%
ATR (14)9.170 USD
Vol Ratio (20d)1.40x

About Revolution Medicines (NASDAQ: RVMD)

›

Revolution Medicines (NASDAQ: RVMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 883 employees.

The shares were at 159.43 USD on 19 November 2026, up 168.7% over 52 weeks. Its 52-week range is 58.91 USD to 220.81 USD: the price is 27.8% below the high and 170.6% above the low.

Its market capitalisation is 34.48B USD.

Revolution Medicines reports return on equity of -69.3%.

It holds more cash than debt, a net cash position of 2.44B USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 24 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 274.68 USD is 72.3% above the current price. The next earnings report is expected on 24 February 2027.